Want to see IN:LYKALABS full AI Analyst Report?
Top Page
Lyka Labs Limited
(LYKALABS)
Select Model
Select Model
Rating:50Neutral
Price Target:
₹83.00
▼(-12.08% Downside)
Action:Reiterated
Date:08/26/26
The score is held back primarily by weakened financial performance (2026 revenue decline, return to losses) and persistently negative free cash flow, despite balance-sheet deleveraging. Technical indicators are relatively strong and provide the main support, while valuation remains unattractive due to negative earnings and no dividend data.
Positive Factors
Debt Reduction
Material deleveraging has improved Lyka Labs’ financial flexibility and reduced the burden carried by operations. Positive equity also provides a stronger capital base than in prior stressed periods, although sustained profitability remains important to preserve this repaired balance-sheet position.
Negative Factors
Revenue and Profitability Reversal
The latest deterioration shows that prior growth and profitability were not yet dependable. Falling revenue combined with a large return to net losses weakens earnings visibility, limits internally generated capital, and raises concern that cost control and operating performance remain inconsistent.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt Reduction
Material deleveraging has improved Lyka Labs’ financial flexibility and reduced the burden carried by operations. Positive equity also provides a stronger capital base than in prior stressed periods, although sustained profitability remains important to preserve this repaired balance-sheet position.
Read all positive factors
Lyka Labs Limited (LYKALABS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.98B
Dividend YieldN/A
Average Volume (3M)3.61K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth-2.60%
EPS Growth-218.87%
CountryIN
Employees648
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.50
Shares Outstanding36,152,710
10 Day Avg. Volume6,237
30 Day Avg. Volume3,611
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.74
Price to Sales (P/S)1.25
P/FCF Ratio-21.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lyka Labs Limited Business Overview & Revenue Model
Company Description
Established in 1976 and headquartered in Mumbai, India, Lyka Labs Limited is a pharmaceutical firm specializing in the development, manufacturing, and marketing of a wide array of pharmaceutical formulations and active pharmaceutical ingredients (...
How the Company Makes Money
Lyka Labs Limited makes money primarily through revenue earned from the sale of its pharmaceutical products. Key revenue streams typically include (1) domestic sales of finished dosage formulations sold to distributors, hospitals, pharmacies, and ...
Lyka Labs Limited Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
52
Neutral
Cash Flow
41
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.38B | 1.28B | 1.41B | 1.05B | 916.90M | 1.84B |
| Gross Profit | 311.71M | 279.37M | 851.35M | 599.41M | 152.84M | 1.30B |
| EBITDA | -5.41M | -36.57M | 201.67M | 167.59M | 128.47M | 1.01B |
| Net Income | -88.99M | -100.32M | 80.12M | -24.89M | -132.12M | 390.00M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.75B | 1.76B | 1.57B | 1.52B | 1.86B |
| Cash, Cash Equivalents and Short-Term Investments | 18.93M | 13.85M | 13.63M | 62.91M | 119.39M | 170.59M |
| Total Debt | 0.00 | 488.69M | 391.84M | 586.50M | 751.02M | 1.30B |
| Total Liabilities | -908.31M | 837.05M | 726.24M | 884.59M | 1.06B | 1.72B |
| Stockholders Equity | 908.31M | 923.93M | 1.04B | 681.54M | 454.41M | 133.38M |
Cash Flow | ||||||
| Free Cash Flow | 51.46M | -75.25M | -137.55M | -74.58M | 7.67M | 717.33M |
| Operating Cash Flow | 136.84M | 36.06M | 18.99M | 17.73M | 89.53M | 792.46M |
| Investing Cash Flow | -46.95M | -111.03M | -117.96M | -94.88M | 73.50M | -61.72M |
| Financing Cash Flow | -91.69M | 75.12M | 52.92M | 19.53M | -216.43M | -631.77M |
Lyka Labs Limited Technical Analysis
Positive
94.40
Price Trends
70.55
Positive
67.36
Positive
67.98
Positive
Market Momentum
3.76
Negative
72.14
Negative
95.22
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LYKALABS, the sentiment is Positive. The current price of 94.4 is above the 20-day moving average (MA) of 75.87, above the 50-day MA of 70.55, and above the 200-day MA of 67.98, indicating a bullish trend. The MACD of 3.76 indicates Negative momentum. The RSI at 72.14 is Negative, neither overbought nor oversold. The STOCH value of 95.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LYKALABS.
Lyka Labs Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹72.74B | 36.58 | ― | 0.11% | 28.14% | 11.38% | |
58 Neutral | ₹4.53B | 27.98 | ― | 0.10% | -3.12% | -8.49% | |
56 Neutral | ₹26.23B | 38.45 | ― | 0.11% | -20.86% | -34.51% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₹2.98B | -33.16 | ― | ― | -2.60% | -218.87% | |
47 Neutral | ₹24.38B | -342.80 | ― | 0.56% | 10.26% | -162.02% | |
44 Neutral | ₹32.98B | -34.68 | ― | 0.09% | 78.89% | -50.10% |
* General Sector Average
IN:LYKALABS
Lyka Labs Limited
82.51
-15.72
-16.00%
IN:DCAL
Dishman Carbogen Amcis Ltd.
167.30
-100.35
-37.49%
IN:PANACEABIO
Panacea Biotec Limited
398.05
-30.90
-7.20%
IN:HALEOSLABS
SMS Lifesciences India Ltd.
1,497.20
294.70
24.51%
IN:SUPRIYA
Supriya Lifescience Limited
903.85
259.22
40.21%
IN:ZOTA
Zota Health Care Ltd.
1,087.20
-412.76
-27.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.